Malaysia Insulin Infusion Pump Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Historical Data Period | 2021 - 2025 |
| Base Year Market Size (2026) | USD 0.85 Million |
| Market Size (2027) | USD 0.87 Million |
| Market Size (2032) | USD 0.99 Million |
| Growth Rate (2027 - 2032) | 2.60 % |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Malaysia Insulin Infusion Pump Market Analysis by Mordor Intelligence
The Malaysia Insulin Infusion Pump Market size is projected to expand from USD 0.85 million in 2026 and USD 0.87 million in 2027 to USD 0.99 million by 2032, registering a CAGR of 2.60% between 2027 and 2032.
According to the Agency for Clinical Research (ICR), a research agency affiliated with the National Institutes of Health (NIH), seven out of ten patients who died from COVID-19 in Malaysia had diabetes. The NHMS also discovered that around 8.1% of Malaysia's adult population, or 1.7 million people, have all three risk factors for diabetes, hypertension, and high cholesterol, the three major noncommunicable illnesses. Diabetes, according to STAT, is characterized by a chronic inflammatory condition that may result in a greater response to COVID-19 or an immunological overreaction that may cause organ damage. Diabetes can also compromise the immune system, and people with type-2 diabetes have more ACE2 receptors in numerous organs, making them more vulnerable to COVID-19 invasion.
Regarding diabetes gadgets, the monitoring category has a substantial market share. Over 100 million individuals worldwide need insulin, including all Type-1 diabetics and 10% to 25% of Type-2 diabetics, who are all required to regularly monitor their glucose levels. Insulin production is exceedingly complex, with just a few manufacturers on the market. As a result, there is fierce competition among these businesses, which always strive to match patient demands by providing the highest-quality insulin.
According to the National Diabetes Registry (NDR) of the Ministry of Health, 84% of diabetes patients in Malaysia are overweight, with young Malaysians aged 18 to 40 being among them. The government is currently investigating the Sama-Sama project, which aims to empower family members and carers to help individuals living with diabetes to enhance disease control and outcomes.
In reality, underlying comorbidities account for most coronavirus mortality in Malaysia, with diabetes and hypertension topping the list and driving the market throughout the forecast period.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Market Trends and Insights
Insulin Pump is Expected to Witness Growth Over the Forecast Period
An insulin pump is a compact medical device that administers insulin continuously throughout the day or in additional doses when needed, closely replicating the function of a healthy pancreas. It offers an alternative to multiple daily insulin injections and insulin pens. Insulin pump therapy is a widely accepted insulin delivery approach for individuals with type 1 diabetes mellitus (T1DM). These devices are an established treatment option for T1DM patients across all age groups, as they provide insulin delivery that more closely matches the body’s natural requirements when pancreatic insulin production is inadequate. Users can adjust basal insulin rates and deliver bolus doses to manage blood glucose levels around meals and physical activity. Remote-controlled insulin pumps also enable parents to pause insulin delivery or administer a bolus dose from a distance while their child is playing or eating.
The government is collaborating with the private sector to develop a program to train healthcare staff and, eventually, carers. Malaysia has the highest diabetes incidence in the Western Pacific and one of the highest in the world, with an annual cost of more than 600 million US dollars. Several variables, including population increase, aging, urbanization, and growing obesity and physical inactivity, contribute to the emerging trend. The growing prevalence of diabetes and its effects in Malaysia motivated this study to comprehensively identify, define, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Insulin therapy is the most effective hypoglycemic drug for diabetes treatment; nonetheless, insulin strength deteriorates when inadequately managed. NCDs, including diabetes, are responsible for more than 70% of all fatalities in Malaysia.
The growing prevalence of diabetes and its effects in Malaysia prompted this study to comprehensively identify, characterize, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Although the use of insulin pumps has expanded dramatically in the West, particularly among type 1 diabetics, it is still quite restricted in Malaysia. The basal insulin infusion, which replaces intermediate- or long-acting subcutaneous insulin injections, delivers insulin continuously throughout the day at predetermined rates adjusted based on the individual's needs.
Owing to the above factors, the market will likely continue to grow.
Rising diabetes prevalence in the country is anticipated to boost the market studied
Diabetes and prediabetes are rising in Malaysia; thus, the government is implementing diabetes prevention and control campaigns nationwide. The Malaysian government should take a comprehensive approach and plan to enhance diabetes awareness, control, prevention, and treatment to minimize the incidence of diabetes in the country. Overweight and obesity contribute significantly to Malaysia's younger diabetic population.
According to the National Health and Nutrition Survey, one in every two Malaysian people is overweight or obese. Diabetes patients have excessive levels of glucose or sugar in their blood. It is a condition caused by the body's inability to produce enough insulin to manage blood sugar levels. It can also be caused by the body's inefficient insulin utilization, known as insulin resistance. Obesity, bad eating habits, sedentary lifestyles, and heredity influence this process.
The government is working with the commercial sector on a program to train healthcare personnel and, eventually, carers. The government is currently investigating the Sama-Sama project, which aims to empower family members and carers to help individuals living with diabetes to enhance disease control and outcomes. It is also working with the private sector on a training program.
As a result, Malaysia's Insulin Pump Devices market is predicted to expand gradually in the coming years.
Competitive Landscape
Market Concentration
Due to the existence of only a few big businesses operating internationally and locally, the insulin infusion pump industry is concentrated. The competitive landscape includes examining a few well-known worldwide and local organizations, such as Medtronic PLC, Insulet Corporation, Ypsomed, Ascensia Diabetes Care, and Tandem Diabetes Care.
Malaysia Insulin Infusion Pump Industry Leaders
-
Medtronics
-
Ascensia Diabetes Care
-
Insulet Corporation
-
Tandem Diabetes Care
-
Ypsomed
- *Disclaimer: Major Players sorted in no particular order
Malaysia Insulin Infusion Pump Market Companies Covered in this Report
- Medtronic
- Insulet
- Ypsomed
- Ascensia
- Tandem Diabetes Care
Recent Industry Developments in Malaysia Insulin Infusion Pump Market
- August 2024: Insulet opened a RM1 billion (USD 200 million) manufacturing facility in Johor Bahru, Malaysia, to produce its tubeless Omnipod insulin delivery systems.
- June 2026: Biocon’s partner, Duopharma Biotech Berhad, secured new multi-year insulin contracts from the Ministry of Health (MoH) Malaysia valued at over MYR 225 million (USD 55.44 million), supported by Biocon's integrated manufacturing facility in Johor, Malaysia.
Malaysia Insulin Infusion Pump Market Report Scope
An insulin pump delivers insulin to control blood sugar and minimize hypoglycemia's effects. The pump comprises a pump reservoir like an insulin cartridge, a battery-operated pump, and a computer chip that allows the user to control the exact amount of insulin being delivered. The pump is attached to a thin plastic tube (an infusion set) with a soft cannula (or needle) at the end through which insulin passes. Malaysia's insulin infusion pumps market is segmented by components (pump device, infusion set, and reservoir). The report offers the value (USD) and Volume (units) for the above segments.
Segmentation Overview
| Insulin Pump Device |
| Infusion Set |
| Reservoir |
| Insulin Infusion Pump | Insulin Pump Device |
| Infusion Set | |
| Reservoir |
Key Questions Answered in the Report
How big is the Malaysia Insulin Infusion Pump Market?
The Malaysia Insulin Infusion Pump Market size is expected to reach USD 0.87 million in 2027 and grow at a CAGR of 2.60% to reach USD 0.99 million by 2032.
What is the current Malaysia Insulin Infusion Pump Market size?
In 2026, the Malaysia Insulin Infusion Pump Market size is expected to reach USD 0.85 million.
Who are the key players in Malaysia Insulin Infusion Pump Market?
Medtronics, Ascensia Diabetes Care, Insulet Corporation, Tandem Diabetes Care and Ypsomed are the major companies operating in the Malaysia Insulin Infusion Pump Market.
What years does this Malaysia Insulin Infusion Pump Market cover, and what was the market size in 2025?
In 2025, the Malaysia Insulin Infusion Pump Market size was estimated at USD 0.83 million. The report covers the Malaysia Insulin Infusion Pump Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the Malaysia Insulin Infusion Pump Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.